UICC and WHO to host virtual dialogue on HPV-based cervical cancer screening
The session will explore translating new WHO guidance into practice using experiences from Mongolia and Malawi.

The Union for International Cancer Control (UICC) and the World Health Organization (WHO) will host a virtual dialogue titled 'From guidance to practice: advancing HPV-based cervical cancer screening'. The event is scheduled for Thursday 12 November from 11:00-12:00 CET.
WHO experts will present the latest guidance and discuss how recommendations on HPV genotyping and program implementation can support countries in strengthening screening strategies, risk-based management, and sustainable scale-up. The dialogue will draw on experiences from Mongolia and Malawi to explore how new WHO guidance can be translated into practice.
Speakers include Dr Mariluz Hernandez Viadel from the World Health Organization, Dr Tsetsegsaikhan Batmunkh from the Ministry of Health and National Cancer Council of Mongolia, Maud Mwakasungula from the Women’s Coalition Against Cancer (WOCACA) in Malawi, and Timothy Tchereni H. from the Clinton Health Access Initiative, Inc. (CHAI) in Malawi. Sabrina Zucchello from the UICC will moderate the session.
The guidance reaffirms HPV DNA testing as the preferred primary screening tool over traditional Pap smears or Visual Inspection with Acetic Acid due to higher sensitivity and negative predictive value. The reliability of molecular testing allows health systems to extend screening intervals to five to ten years for the general population.
The WHO emphasizes self-collected vaginal sampling as a critical delivery mechanism to overcome cultural and access barriers. The guidance also outlines steps for health system planning, supply chain stability, laboratory quality assurance, and workforce training.
Key facts
- The virtual dialogue will take place on Thursday 12 November from 11:00-12:00 CET.
- HPV DNA testing is the preferred primary screening tool over traditional Pap smears or Visual Inspection with Acetic Acid.
- Molecular testing reliability allows health systems to extend screening intervals to five to ten years for the general population.
Perspectives
Neutral
The UICC and WHO will host a virtual dialogue on Thursday 12 November to discuss advancing HPV-based cervical cancer screening using guidance and experiences from Mongolia and Malawi.
Positive
The guidance provides actionable operational strategies and emphasizes self-collected vaginal sampling to overcome cultural and access barriers.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.